

UN NOUVEAU TRAITEMENT PERCUTANE DE L'ANGOR REFRACTAIRE





Julien ADJEDJ

Saint Laurent du Var, France

Introduction




Claude
Schaeffer
Beck
(1894-
1971)




Mécanisme

Perfusion coronaire normale




Mécanisme

Perfusion coronaire ischémique



Mécanisme

Perfusion coronaire ischémique & augmentation pression sinus coronaire



Données cliniques


The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE


Efficacy of a Device to Narrow the Coronary Sinus in Refractory Angina

Stefan Verheye, M.D., Ph.D., E. Marc Jolicœur, M.D., Miles W. Behan, M.D., Thomas Pettersson, M.D., Paul Sainsbury, M.D., Jonathan Hill, M.D., Mathias Vrolix, M.D., Pierfrancesco Agostoni, M.D., Thomas Engstrom, M.D., Marino Labinaz, M.D., Ranil de Silva, M.D., Marc Schwartz, R.C.I.S., Nathalie Meyten, M.D., Neal G. Uren, M.D., Serge Doucet, M.D., Jean-François Tanguay, M.D., Steven Lindsay, M.D., Timothy D. Henry, M.D., Christopher J. White, M.D., Elazer R. Edelman, M.D., Ph.D., and Shmuel Banai, M.D.

COSIRA trial



Données cliniques



COSIRA trial

Données cliniques



Coronary Sinus Reducer Implantation for the Treatment of Chronic Refractory Angina

A Single-Center Experience

Francesco Giannini, MD, Luca Baldetti, MD, Francesco Ponticelli, MD, Neil Ruparelia, MD, Satoru Mitomo, MD, Azeem Latib, MD, Matteo Montorfano, MD, Richard J. Jabbour, MD, Andrea Aurelio, MD, Luca Ferri, MD, Antonio Mangieri, MD, Damiano Regazzoli, MD, Marco Ancona, MD, Matteo Pagnesi, MD, Alessia Faccini, MD, Alaide Chieffo, MD, Lorenzo Azzalini, MD, Mauro Carlino, MD, Antonio Colombo, MD

Baseline	n=50
Mean age (years)	68
Male	82%
Diabetes Mellitus	44%
Previous PCI	76%
Previous CABG	56%




Procedural success: 100%

No device-related adverse effects during the procedure or follow-up




Données cliniques



- Mean CCS Class reduction: from 2.98 ± 0.52 to 1.67 ± 0.83 ($p < 0.001$)
- At least 1 CCS Class reduction: 80% patients
- At least 2 CCS Class reduction: 40% patients



Coronary Sinus Reducer implantation Mars 2022




Coronary Sinus Reducer implantation Mars 2022



Retour sur le mécanisme

Flux absolu par thermodilution coronaire



Retour sur le mécanisme


Flux absolu par Thermodilution coronaire

Impact of the coronary sinus reducer on the coronary artery circulation cases report

Francesco Giannini¹, Léo Cuenin², and Julien Adjedj^{2*}

¹Interventional Cardiology Unit, GVM Care and Research Maria Cecilia Hospital, Cotignola, Italy; and ²Department of Cardiology, Arnauld Tzanck Institute, Saint-Laurent-du-Var, France

Received 22 November 2021; first decision 29 December 2021; accepted 6 April 2022; online publish-ahead-of-print 26 April 2022




Retour sur le mécanisme

Flux absolu par Thermodilution coronaire


n=6

Absolute coronary blood flow




P=0.12

Microvascular Resistances



P=0.03

FFR



P=0.30

Conclusion

Nouvelle technique efficace de l'angor refractaire & INOCA (Remboursée avec registre)

